Polyphor appoints Michael Altorfer as new CEO

19-Mar-2015 - Switzerland

Polyphor Ltd announced the appointment of Michael Altorfer as new CEO and successor of Jean-Pierre Obrecht as of March 31, 2015. Jean-Pierre Obrecht will continue to support the company in his role as a Member of the Board of Directors.

Michael Altorfer joined Polyphor in 2001. He has served Polyphor in various functions, first as Head of the Small Molecule Service Business, then as Chief Financial Officer and Head of Corporate Development, and was Chief Operating Officer since 2014.

Michael Altorfer started his career as a scientist in pharmaceutical research at Sandoz, Ciba-Geigy (Summit, NJ, USA), and Roche. From 1996 to 2001 he held program management and line management roles at the investment bank UBS Warburg. Michael Altorfer studied Natural Sciences at the Swiss Federal Institute of Technology (ETH) in Zurich, with the main focus on chemistry, toxicology, and immunology. He obtained his Ph.D. in Chemistry in 1996 under the supervision of Prof. Dr. H.-J. Hansen (University of Zurich) and Prof. Dr. K. Müller (Roche) and an MBA degree from the University of Rochester, NY, USA.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances